CSL opens Australian biotechnology manufacturing facility

Leading Australian biotech firm CSL Limited (ASX: CSL) has opened the CSL Behring Biotechnology manufacturing facility in Melbourne, Australia, the centerpiece of the group's $250 million expansion at its Broadmeadows site.

The new facility, located adjacent to the site's manufacturing plant for plasma products, will play an increasingly important role in the company's global operations, particularly in the late-stage development of new types of hemophilia products. It is one of the largest and most advanced facilities of its kind in the world and will produce novel recombinant therapies on a large scale for international clinical trials.

"This world-class facility is key to the ongoing success of our global R&D strategy and reflects our commitment to providing better treatment options for people who are managing certain bleeding disorders and other life-threatening conditions," said CSL chief executive Paul Perreault.